NICE TAs

13/08/2020

TA220: Golimumab for the treatment of psoriatic arthritis

13/08/2020

TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (replaced TA42)

13/08/2020

NG131: Prostate cancer: diagnosis and management

13/08/2020

TA197: Dronedarone for the treatment of non-permanent atrial fibrillation

13/08/2020

TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

13/08/2020

TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

13/08/2020

TA432: Everolimus for advanced renal cell carcinoma after previous treatment (replaced TA219)

13/08/2020

TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer

13/08/2020

TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (replaced TA222)

13/08/2020

TA230: Bivalirudin for the treatment of ST-segment-elevation myocardial infarction

13/08/2020

TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (replaced TA205)

13/08/2020

TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma

13/08/2020

TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion

13/08/2020

TA461: Roflumilast for treating chronic obstructive pulmonary disease (replaced TA244)

13/08/2020

TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor

13/08/2020

TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia

13/08/2020

TA274: Ranibizumab for treating diabetic macular oedema (replaced TA237)

13/08/2020

TA236: Ticagrelor for the treatment of acute coronary syndromes

13/08/2020

TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults

13/08/2020

TA149: Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal)